LLY

Business Context and Reporting Period

Company: Eli Lilly & Co.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: Eli Lilly operates primarily in the pharmaceutical products segment, with a smaller animal health segment. The company reported strong sales growth driven by key products including Cymbalta, Cialis, Humalog, Alimta, and Gemzar. Notable corporate events during the period included the appointment of John C. Lechleiter as CEO (effective April 1, 2008) and the termination of the AIR Insulin development program.

Key Financial Metrics

Note: Total debt for Q1 2007 is not explicitly aggregated in the text, though Q1 2008 total debt is stated as $4.72 billion.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 14% to $4.81 billion. Growth was driven by volume (8%), foreign exchange rates (5%), and selling prices (1%).
• Profitability Surge: Net income more than doubled to $1.06 billion. This was significantly aided by a discrete income tax benefit of $210.3 million resulting from the resolution of an IRS audit for tax years 2001-2004.
• Expense Increases:
  • Acquired IPR&D: Charges decreased to $87.0 million from $328.5 million in Q1 2007 (the prior year included a large charge for the ICOS acquisition).
  • Restructuring/Impairments: Charges increased to $145.7 million from $123.0 million, primarily due to the termination of the AIR Insulin program ($91.7 million in wind-down costs and $40.9 million in asset write-downs).
  • Marketing Expenses: Rose 16% to $1.55 billion due to the ICOS acquisition impact, increased marketing for key products, and higher legal costs (including a $15 million Zyprexa settlement with Alaska).
• Cash Position: Cash and cash equivalents decreased slightly by $75.1 million during the quarter, despite strong operating cash flow, due to significant investing activities (net purchases of short-term investments) and financing activities (dividends and debt reduction).

Guidance, Outlook, and Risks

Financial Expectations for 2008

Management expects full-year 2008 earnings per share to range from $3.90 to $4.05. This guidance includes:

• A $0.19 per share benefit from the IRS audit resolution.
• A $0.09 per share charge for asset impairments/restructuring (AIR Insulin).
• A $0.05 per share charge for the BioMS licensing transaction.

The estimated effective tax rate has been revised to approximately 22% (excluding the IRS audit benefit), down from the previously stated 23%.

Management Commentary & Unusual Items

• Product Pipeline: Submitted Byetta for monotherapy approval; received European approval for Alimta and a new indication for Forteo. Received a "not approvable" letter from the FDA for Zyprexa long-acting injection.
• Leadership Change: John C. Lechleiter assumed the role of CEO on April 1, 2008.
• Share Repurchases: No shares were repurchased under the $3.0 billion program in Q1 2008; the company does not expect to repurchase shares for the remainder of 2008.

Risks and Contingencies

• Zyprexa Litigation: Significant ongoing exposure. Approximately 1,270 claims remain unresolved. The company has recorded $1.61 billion in net pretax charges since 2005. Generic competition has launched in Canada and Germany.
• Government Investigations: Ongoing investigations by the U.S. Attorney for the Eastern District of Pennsylvania and over 30 state attorneys general regarding marketing practices for Zyprexa, Prozac, and Prozac Weekly. Potential for fines, penalties, or criminal charges.
• Patent Litigation: Active challenges to patents for Evista, Gemzar, Strattera, and Xigris. Unfavorable outcomes could materially impact operations.
• Product Liability Insurance: The company is largely self-insured for future product liability losses due to a restrictive insurance market.

Investor Verification Checklist

• IRS Audit Impact: Verify the sustainability of the $210.3 million tax benefit and the revised 22% effective tax rate forecast.
• Zyprexa Exposure: Monitor the status of the remaining 1,270 product liability claims and the outcome of the Alaska settlement precedent.
• Generic Competition: Assess the financial impact of generic Zyprexa launches in Canada and Germany and potential future patent expirations for Evista and Gemzar.
• Regulatory Investigations: Track developments in the multi-state investigation into marketing practices, which could result in significant fines.
• AIR Insulin Termination: Confirm that the $145.7 million charge fully captures all wind-down costs and that no further restructuring charges are anticipated from this specific program.